.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,957,924

« Back to Dashboard

Claims for Patent: 4,957,924

Title: Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof
Abstract:The present invention relates to certain amino acid exters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.
Inventor(s): Beauchamp; Lilia M. (Raleigh, NC)
Assignee: Burroughs Wellcome Co. (Research Traingle Park, NC)
Application Number:07/228,377
Patent Claims: 1. A pharmaceutically acceptable salt of 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate.

2. The salt of claim 1, which is an acid addition salt.

3. The salt of claim 1, which is derived from hydrochloric, sulfuric, phosphoric, maleic, fumaric, citric, tartaric, lactic, acetic or p-toluenesulfonic acid.

4. A pharmaceutical composition for use as an antiviral comprising an effective antiviral amount of the compound 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.

5. The composition of claim 4, in which the salt is an acid addition salt.

6. The composition of claim 4, in which the salt is the hydrochloride salt.

7. A tablet or capsule for use as an antiviral comprising an effective antiviral amount of the compound 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.

8. The tablet or capsule of claim 7, in which the salt is an acid addition salt.

9. The tablet or capsule of claim 7, in which the salt is the hydrochloride salt.

10. A method of treating a herpes virus infection in a human comprising administering to said human an effective herpes virus infection treatment amount of the compound 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof.

11. The method of claim 8, in which the salt is an acid addition salt.

12. The method of claim 11, in which the salt is the hydrochloride salt.

13. A method of treating a herpes virus infection in a human comprising orally administering to said human an effective herpes virus treatment amount of the compound 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof.

14. The method of claim 13, in which the herpes virus infection is a herpes simplex or herpes zoster infection.

15. A method of treating a hepatitis B virus or Epstein Barr virus infection in a human, which comprises administering to said human an effective hepatitis B virus or Epstein Barr virus infection treatment amount of the compound 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof.

16. The method of claim 15, in which the salt is an acid addition salt.

17. 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate hydrochloride.

18. 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate.

19. A method of generating acyclovir in the plasma of a mammal, which comprises orally administering the compound 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof to said mammal.

20. The method of claim 19, in which an acid addition salt is orally administered.

21. The method of claim 19, in which the hydrochloride salt is orally administered.

22. The hydrochloride salt of 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate.

23. The method of treating a CMV infection in a human, which comprises administering to said human an effective CMV treatment amount of 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate or a pharmaceutically acceptable salt thereof.

24. The method of claim 23, in which the salt is an acid addition salt.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc